Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Department of Neurosurgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Eur J Radiol. 2021 Jan;134:109466. doi: 10.1016/j.ejrad.2020.109466. Epub 2020 Dec 3.
Accurate glioma grading and IDH mutation status prediction are critically essential for individualized preoperative treatment decisions. This study aims to compare the diagnostic performance of magnetic resonance (MR) amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction.
Fifty-one glioma patients without treatment were retrospectively included. APT-weighted (APTw) effect and DKI indices, including mean diffusivity (MD), fractional anisotropy (FA), mean kurtosis (MK), and kurtosis FA (KFA) were obtained from APT and diffusion-weighted images, respectively. DKI indices in tumors were normalized to that in contralateral normal appearing white matter (CNAWM) and the APTw difference (ΔAPTw) between the two regions was calculated. Student's t-test, one-way ANOVA and ROC analyses were conducted.
Among the enrolled 51 patients, 13 had glioma-II, 17 had glioma-III and 21 had glioma-IV. 25 patients were diagnosed as IDH-mutant, and 26 as IDH-wild type. MD and MK differed significantly between glioma-IV and glioma II/III (P < 0.05), but not between glioma-II and glioma-III. FA and KFA showed no significant difference among the three groups (P > 0.05). IDH-mutant group exhibited significantly higher MD and lower FA, MK and ΔAPTw than IDH-wild type (P < 0.05), whereas the two groups showed comparable KFA values. In contrast, ΔAPTw differed significantly across tumor grades and IDH mutation status (P < 0.05), with consistently better discriminatory performance than DKI indices in glioma grading and IDH mutation status prediction.
APT imaging was superior to DKI in glioma grading and IDH mutation status prediction, benefiting accurate diagnoses and treatment decisions.
准确的胶质瘤分级和 IDH 突变状态预测对个体化术前治疗决策至关重要。本研究旨在比较磁共振酰胺质子转移(APT)和扩散峰度成像(DKI)在胶质瘤分级和 IDH 突变状态预测中的诊断性能。
回顾性纳入 51 例未经治疗的胶质瘤患者。从 APT 和弥散加权图像中分别获得 APT 加权(APTw)效应和 DKI 指数,包括平均弥散度(MD)、各向异性分数(FA)、平均峰度(MK)和峰度 FA(KFA)。肿瘤内的 DKI 指数与对侧正常表现白质(CNAWM)进行归一化,并计算两个区域之间的 APTw 差值(ΔAPTw)。进行了学生 t 检验、单因素方差分析和 ROC 分析。
在纳入的 51 例患者中,13 例为胶质瘤-II 级,17 例为胶质瘤-III 级,21 例为胶质瘤-IV 级。25 例患者被诊断为 IDH 突变型,26 例为 IDH 野生型。MD 和 MK 在胶质瘤-IV 级和胶质瘤-II/III 级之间有显著差异(P < 0.05),但在胶质瘤-II 级和胶质瘤-III 级之间无显著差异。FA 和 KFA 在三组之间无显著差异(P > 0.05)。IDH 突变型组的 MD 明显高于 IDH 野生型,FA、MK 和 ΔAPTw 明显低于 IDH 野生型(P < 0.05),而两组的 KFA 值相当。相反,ΔAPTw 在肿瘤分级和 IDH 突变状态方面有显著差异(P < 0.05),在胶质瘤分级和 IDH 突变状态预测方面具有更好的鉴别性能。
APT 成像在胶质瘤分级和 IDH 突变状态预测方面优于 DKI,有助于准确诊断和治疗决策。